EUCTR2016-002554-21-IT进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy - A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and s
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 490
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Participants with probable or possible PSP
- •-Able to ambulate independently or with assistance
- •-Able to tolerate MRI
- •-Have reliable caregiver to accompany participant to all study visits
- •-Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at
- •-Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 138
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 321
排除标准
- •-Presence of other significant neurological or psychiatric disorders
- •-Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neauron disease
- •-History of early, prominent rapid eye movement (REM) sleep behaviour disorder
- •-History of or screening brain MRI scan indicative of significant abnormality
- •-Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay
研究者
相似试验
进行中（未招募）
1 期
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabMedDRA version: 19.0Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disordersAcute coronary syndromeEUCTR2011-005698-21-PLsanofi-aventis Recherche & Développement18,600
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of MigraineProphylaxis of migraine with or without aura, in patients with a diagnosis of at least 1-year duration.MedDRA version: 6.1Level: PTClassification code 10027607EUCTR2004-004162-33-ITJANSSEN-CILAG
进行中（未招募）
1 期
A study of Baricitinib in patients with LupusSystemic Lupus Erythematosus (SLE)MedDRA version: 21.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemicSystem Organ Class: 100000004859EUCTR2017-005026-37-HREli Lilly and Company825
已完成
3 期
This study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.CTRI/2010/091/002997Johnson Johnson Ltd720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Anti-Allergic Effects of Continuous Ingestion of Lactococcus lactis subsp. cremoris YRC3780Healthy adultsJPRN-UMIN000021215Hokkaido Information University96